KING OF PRUSSIA, Pa. and MONTREAL, Feb. 16, 2011 /PRNewswire/ —
As a means of aiding the World Federation of Hemophilia’s (WFH)
progress in improving the diagnosis and treatment of hemophilia in
developing countries through its Global Alliance for Progress (GAP)
program, CSL Behring has committed to
donating more factor VIII concentrate (FVIII) to WFH. The donated
product will be used in South America, Thailand, the Philippines,
parts of eastern Europe, parts of the Middle East, and in Tunisia.
The donation, the total market value of which is approximately
$500,000, will be made using coagulation factor concentrate with a
minimum shelf-life of one year.
CSL Behring has pledged to support the WFH with separate
financial contributions totaling nearly $1 million over a period of
three years. This most recent donation is part of that
“As a long-standing contributor to GAP, CSL Behring is pleased
to once again be in a position to assist hemophilia patients who
have a critical need for safe, effective medical therapies,” said
Peter Turner, President and Chief Executive Officer of CSL Behring.
“We are also gratified to be a partner with WFH in this effort, an
organization that continues to make a large and positive difference
in the world. Our commitment to their progress remains strong.”
“The WFH relies on product donations to help introduce clotting
factor concentrates in developing countries and these donations
serve as a catalyst for improving care,” said Claudia Black, Chief
Executive Officer of the WFH. “We are grateful to our industry
partners such as CSL Behring, who provide, among other resources,
valuable and life-saving medicine, including this most recent
donation of coagulation factor. “
VIII is an essential blood clotting factor that can be given to
hemophiliacs to restore hemostasis.